Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 Apr 2019
Historique:
received: 28 02 2019
revised: 29 03 2019
accepted: 03 04 2019
entrez: 10 4 2019
pubmed: 10 4 2019
medline: 28 7 2019
Statut: epublish

Résumé

Polyphenols are natural antioxidant compounds ubiquitously found in plants and, thus, ever present in human nutrition (tea, wine, chocolate, fruits and vegetables are typical examples of polyphenol-rich foods). Widespread evidence indicate that polyphenols exert strong antioxidant, anti-inflammatory, anti-microbial and anti-cancer activities, and thus, they are generally regarded to as all-purpose beneficial nutraceuticals or supplements whose use can only have a positive influence on the body. A closer look to the large body of results of years of investigations, however, present a more complex scenario where polyphenols exert different and, sometimes, paradoxical effects depending on dose, target system and cell type and the biological status of the target cell. Particularly, the immunomodulatory potential of polyphenols presents two opposite faces to researchers trying to evaluate their usability in future cancer therapies: on one hand, these compounds could be beneficial suppressors of peri-tumoral inflammation that fuels cancer growth. On the other hand, they might suppress immunotherapeutic approaches and give rise to immunosuppressive cell clones that, in turn, would aid tumor growth and dissemination. In this review, we summarize knowledge of the immunomodulatory effects of polyphenols with a particular focus on cancer microenvironment and immunotherapy, highlighting conceptual pitfalls and delicate cell-specific effects in order to aid the design of future therapies involving polyphenols as chemoadjuvants.

Identifiants

pubmed: 30959898
pii: ijms20071714
doi: 10.3390/ijms20071714
pmc: PMC6479528
pii:
doi:

Substances chimiques

Immunologic Factors 0
Polyphenols 0

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Università degli Studi di Roma Tor Vergata
ID : E81I18000330005

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Immunol Res. 2003;27(2-3):565-74
pubmed: 12857999
Biochem Pharmacol. 2003 Dec 15;66(12):2427-35
pubmed: 14637200
Am J Clin Nutr. 2004 May;79(5):727-47
pubmed: 15113710
Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S
pubmed: 15640486
J Immunol. 2005 Jun 15;174(12):8116-24
pubmed: 15944320
Crit Rev Food Sci Nutr. 2005;45(4):287-306
pubmed: 16047496
J Leukoc Biol. 2006 Mar;79(3):586-95
pubmed: 16415169
Immunology. 2006 Apr;117(4):433-42
pubmed: 16556256
Clin Exp Immunol. 2007 Jan;147(1):155-63
pubmed: 17177975
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
Int Immunopharmacol. 2008 Apr;8(4):542-7
pubmed: 18328445
Trends Immunol. 2008 Jun;29(6):272-9
pubmed: 18468488
Leuk Res. 2009 Jun;33(6):823-8
pubmed: 19010542
Mol Carcinog. 2009 Aug;48(8):713-23
pubmed: 19142898
Curr Protoc Immunol. 2009 Apr;Chapter 20:Unit 20.11
pubmed: 19347848
Curr Top Microbiol Immunol. 2011;350:127-47
pubmed: 20680806
Int Immunopharmacol. 2011 Sep;11(9):1234-40
pubmed: 21497674
Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):200-20
pubmed: 21827399
Int Immunopharmacol. 2011 Nov;11(11):1877-86
pubmed: 21854876
Crit Rev Food Sci Nutr. 2011 Jul;51(6):524-46
pubmed: 21929330
Immunotherapy. 2011 Oct;3(10):1235-51
pubmed: 21995574
Semin Cancer Biol. 2012 Aug;22(4):298-306
pubmed: 22414911
J Ethnopharmacol. 2012 Jun 14;141(3):888-94
pubmed: 22465146
PLoS One. 2012;7(4):e35650
pubmed: 22532866
Front Biosci (Landmark Ed). 2012 Jun 01;17:2396-418
pubmed: 22652788
Oncoimmunology. 2012 May 1;1(3):326-333
pubmed: 22737608
Biomed Pharmacother. 2013 Feb;67(1):43-7
pubmed: 23218986
Biochem Biophys Res Commun. 2013 Feb 8;431(2):348-53
pubmed: 23291179
Int J Immunopathol Pharmacol. 2013 Jan-Mar;26(1):117-25
pubmed: 23527714
Biochim Biophys Acta. 2013 Aug;1836(1):177-85
pubmed: 23648450
Ann N Y Acad Sci. 2013 May;1284:1-5
pubmed: 23651186
Front Biosci (Landmark Ed). 2013 Jun 01;18:1290-310
pubmed: 23747884
Front Oncol. 2013 May 29;3:137
pubmed: 23755374
Front Oncol. 2013 Jul 26;3:197
pubmed: 23898464
In Vivo. 2013 Sep-Oct;27(5):627-34
pubmed: 23988898
BMC Cancer. 2013 Sep 17;13:421
pubmed: 24044575
Cancers (Basel). 2011 Oct 13;3(4):3856-93
pubmed: 24213115
Cancer Microenviron. 2014 Aug;7(1-2):1-9
pubmed: 24357332
Cancer Immunol Res. 2014 Mar;2(3):194-9
pubmed: 24778315
Molecules. 2014 May 22;19(5):6694-706
pubmed: 24858101
Cold Spring Harb Perspect Biol. 2014 Jun 02;6(6):null
pubmed: 24890514
J Inflamm Res. 2014 Jun 17;7:89-101
pubmed: 24971028
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Front Immunol. 2014 Jul 21;5:325
pubmed: 25101077
BMC Complement Altern Med. 2014 Aug 30;14:322
pubmed: 25175005
Oncotarget. 2014 Nov 15;5(21):10745-62
pubmed: 25296980
Semin Oncol. 2014 Oct;41 Suppl 5:S3-13
pubmed: 25438997
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Immunotherapy. 2014;6(12):1265-78
pubmed: 25524383
Cell Biochem Biophys. 2015 Jun;72(2):617-25
pubmed: 25605266
PLoS One. 2015 Feb 11;10(2):e0115686
pubmed: 25671635
Semin Cancer Biol. 2015 Dec;35 Suppl:S185-S198
pubmed: 25818339
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Int J Mol Sci. 2015 Apr 24;16(5):9236-82
pubmed: 25918934
Trends Immunol. 2015 Jun;36(6):344-53
pubmed: 25981968
Dis Model Mech. 2015 Apr;8(4):337-50
pubmed: 26035842
Cancer J. 2015 Jul-Aug;21(4):250-3
pubmed: 26222075
Mol Ther. 2016 Feb;24(2):364-374
pubmed: 26334519
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
Oncoimmunology. 2015 Apr 2;4(9):e1027472
pubmed: 26405598
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Adv Anat Pathol. 2016 May;23(3):180-91
pubmed: 27058246
PLoS One. 2016 Apr 14;11(4):e0153682
pubmed: 27077371
Nutrients. 2016 May 09;8(5):
pubmed: 27171110
Int Immunol. 2016 Jul;28(7):319-28
pubmed: 27235694
Cell Death Dis. 2016 Jun 02;7(6):e2243
pubmed: 27253407
Chem Biol Interact. 2016 Aug 25;256:111-24
pubmed: 27378625
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
FEBS Open Bio. 2016 Apr 21;6(6):548-57
pubmed: 27419057
Int Immunopharmacol. 2016 Oct;39:265-272
pubmed: 27497194
Pharmacol Rep. 2016 Oct;68(5):1065-8
pubmed: 27552061
Vaccines (Basel). 2016 Nov 03;4(4):
pubmed: 27827871
Immunotherapy. 2017 Jan;9(1):83-97
pubmed: 28000524
Oncotarget. 2017 May 23;8(21):34405-34422
pubmed: 28159921
Int Rev Cell Mol Biol. 2017;330:295-342
pubmed: 28215534
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Am J Transl Res. 2017 Apr 15;9(4):1866-1875
pubmed: 28469791
Ther Adv Med Oncol. 2017 Apr;9(4):235-252
pubmed: 28491145
Nutrients. 2017 May 20;9(5):null
pubmed: 28531112
Oxid Med Cell Longev. 2017;2017:6781872
pubmed: 28546852
Onco Targets Ther. 2017 May 22;10:2675-2683
pubmed: 28579805
Mol Cancer Res. 2017 Sep;15(9):1127-1137
pubmed: 28596419
Eur J Pharmacol. 2017 Oct 5;812:91-96
pubmed: 28690190
J Cell Biochem. 2018 Feb;119(2):1420-1428
pubmed: 28731226
Mol Nutr Food Res. 2017 Dec;61(12):
pubmed: 28815947
Semin Cancer Biol. 2017 Oct;46:158-181
pubmed: 28823533
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Scand J Immunol. 2017 Dec;86(6):436-443
pubmed: 28941312
Clin Transl Immunology. 2017 Sep 15;6(9):e154
pubmed: 28983402
Oncoimmunology. 2017 Jul 31;6(11):e1356151
pubmed: 29147611
Front Immunol. 2017 Oct 27;8:1401
pubmed: 29163482
Oncotarget. 2017 Oct 17;8(53):90630-90631
pubmed: 29207589
Signal Transduct Target Ther. 2016 Nov 18;1:16025
pubmed: 29263903
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
Molecules. 2018 Jan 18;23(1):null
pubmed: 29346317
Immunol Lett. 2018 Apr;196:11-21
pubmed: 29407608
Cancer Immunol Immunother. 2018 May;67(5):761-774
pubmed: 29453519
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Front Oncol. 2018 Mar 28;8:86
pubmed: 29644214
Curr Pharm Biotechnol. 2018;19(1):5-18
pubmed: 29667553
Arch Oral Biol. 2018 Aug;92:32-37
pubmed: 29751146
Front Immunol. 2018 Jun 14;9:1364
pubmed: 29963056
Int J Oncol. 2018 Oct;53(4):1469-1480
pubmed: 30066852
Molecules. 2018 Aug 18;23(8):null
pubmed: 30126206
Front Oncol. 2018 Aug 30;8:356
pubmed: 30234017
Int J Mol Sci. 2018 Sep 20;19(10):null
pubmed: 30241395
J Cancer Res Clin Oncol. 2018 Dec;144(12):2433-2440
pubmed: 30293118
J Exp Clin Cancer Res. 2018 Oct 29;37(1):261
pubmed: 30373602
Nutrients. 2018 Nov 02;10(11):null
pubmed: 30400131
Anticancer Agents Med Chem. 2018 Nov 09;:null
pubmed: 30411693
Int J Mol Sci. 2019 Jan 14;20(2):null
pubmed: 30646518
Precis Clin Med. 2018 Sep;1(2):65-74
pubmed: 30687562
Immunotherapy. 2019 Jan;11(1):15-20
pubmed: 30702010
Immunity. 1995 Nov;3(5):541-7
pubmed: 7584144

Auteurs

Chiara Focaccetti (C)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. chiara_focaccetti@hotmail.com.

Valerio Izzi (V)

Oulu Center for Cell-Matrix Research, University of Oulu, FIN-90014 Oulu, Finland. valerio.izzi@oulu.fi.

Monica Benvenuto (M)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. monicab4@hotmail.it.

Sara Fazi (S)

Department of Experimental Medicine, University of Rome "Sapienza", 00164 Rome, Italy. sarafazi@hotmail.it.

Sara Ciuffa (S)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. saramhh@hotmail.it.

Maria Gabriella Giganti (MG)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. giganti@med.uniroma2.it.

Vito Potenza (V)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. vitopotenza2@virgilio.it.

Vittorio Manzari (V)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. manzari@med.uniroma2.it.

Andrea Modesti (A)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. modesti@med.uniroma2.it.

Roberto Bei (R)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy. bei@med.uniroma2.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH